• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Development and validation of an ultrahigh performance liquid chromatography ‐high resolution tandem mass spectrometry quantification method for hypoglycin A and methylene cyclopropyl acetic acid carnitine in horse serum in cases of atypical myopathy
Abstract Atypical myopathy (AM) is a fatal disease in horses presumably caused by hypoglycine A (HGA) from ingested maple seeds and its active metabolite methylene cyclopropyl acetic acid (MCPA). The aim of this study was the development and validation of a rapid and simple assay for HGA and MCPA‐carnitine in horse serum and its application to authentic samples. Identification and quantification were carried out by ultra high performance liquid chromatography–high resolution tandem mass spectrometry (UHPLC–HRMS/MS) with full‐scan/data‐dependent MS/MS. Chromatographic separation was performed by isocratic elution ...
Source: Drug Testing and Analysis - December 12, 2017 Category: Drugs & Pharmacology Authors: Wiebke Rudolph, Daniela Remane, Dirk K. Wissenbach, Carmen Klein, Dirk Barnewitz, Frank T. Peters Tags: RESEARCH ARTICLE Source Type: research

Proton Pump Inhibitors: Risk for Myopathy?
CONCLUSION: A limited body of published data suggests that PPI use has been associated with myopathy-like symptoms without long-term effects following discontinuation. Although myopathy is a rare adverse effect observed with PPIs, it can be a serious side effect to be considered when starting a patient on acid suppression therapy. PMID: 27539734 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 17, 2016 Category: Drugs & Pharmacology Authors: Colmenares EW, Pappas AL Tags: Ann Pharmacother Source Type: research

Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease
This report is first case of rhabdomyolysis associated with initiation of febuxostat. Febuxostat should be withdrawn when rhabdomyolysis is confirmed. This report is first case of rhabdomyolysis associated with initiation of febuxostat. Febuxostat should be withdrawn when rhabdomyolysis is confirmed.
Source: Journal of Clinical Pharmacy and Therapeutics - March 11, 2014 Category: Drugs & Pharmacology Authors: Y. Kang, M. J. Kim, H. N. Jang, E. J. Bae, S. Yun, H. S. Cho, S.‐H. Chang, D. J. Park Tags: Case Report Source Type: research